FDA delays key drug approval by 3 months due to leadership vacuum

With the FDA Commissioner's resignation and no permanent successor named, the review timeline for a pending blockbuster drug (e.g., Alzheimer's or cancer treatment) will exceed the original 10-month target. Internal restructuring and acting leadership will slow decision-making.

Implied probability (Yes)

72%